D-TORCH: Topical Diclofenac for Reducing Hand Foot Syndrome with Capecitabine

Opinion
Video

Heather Moore, CPP, PharmD examines the role of topical diclofenac gel in the management of hand and foot syndrome associated with capecitabine, highlighting key insights from the D-TORCH trial.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Related Content
53 Comparison of Surgical Complications With Direct-to-Implant vs Tissue Expander Reconstruction After Wise Pattern Skin-Sparing Mastectomy

53 Comparison of Surgical Complications With Direct-to-Implant vs Tissue Expander Reconstruction After Wise Pattern Skin-Sparing Mastectomy

Areej Alhumaid;Alexandra Lopez-Aguiar;Kristin E. Rojas;Jessica Crystal;John Oeltjen;Devinder Singh;Susan B. Kesmodel
May 22nd 2025
Article
Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

54 The Treatment of Breast Cancer With Percutaneous Thermal Ablation: Results of the THERMAC Trial

54 The Treatment of Breast Cancer With Percutaneous Thermal Ablation: Results of the THERMAC Trial

Linda Riks;Sophie Wooldrik;Taco Klem;Gerson Struik
May 21st 2025
Article
Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

55 Do Genetic Counseling and Testing Affect Rates of Contralateral Prophylactic Mastectomy in Patients Without Clinically Actionable Mutations?

55 Do Genetic Counseling and Testing Affect Rates of Contralateral Prophylactic Mastectomy in Patients Without Clinically Actionable Mutations?

Natalie Garver;Valerie L. Staradub, MD;Christopher Verdone;Kelly Mackessy;Alexandra Haraczy;Lianteng Zhi
May 20th 2025
Article
56 Paternal vs Maternal Inheritance of a BRCA Mutation: Is There a Difference in Presentation and Stage of Breast Cancer at Diagnosis?

56 Paternal vs Maternal Inheritance of a BRCA Mutation: Is There a Difference in Presentation and Stage of Breast Cancer at Diagnosis?

Erika King;Elisa Port;Borna Mohabbatizadeh;Christina Weltz;Jacquelyn Dillon;Jacquelyn Amenta;Mayuri Jain
May 19th 2025
Article
OSZAR »